AdventHealth, Moffitt form collaboration

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Moffitt Cancer Center and AdventHealth are partnering to provide cancer treatment and better access to cancer prevention, education, cancer screenings and early phase clinical trials for patients in Florida.

The partnership will develop a cancer research agenda shared across both organizations, which will include expanding research activities and recruitment of innovative cancer investigators to the AdventHealth Orlando and Celebration campuses.

The two organizations plan to establish a clinical research facility and chemotherapy/immunotherapy infusion program at AdventHealth Celebration, focused on solid tumor malignancies and malignant hematology, which will allow Central Florida patients to receive critical treatments closer to home.

At AdventHealth Celebration, researchers from both organizations will conduct early phase clinical studies—the first and only phase I site in Central Florida.

This partnership extends to AdventHealth’s West Florida division as well, where a new Moffitt outpatient satellite cancer center is under construction at AdventHealth Wesley Chapel.

Table of Contents

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login